2. Academic Validation
  3. Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma

Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma

  • Cancer Res. 2022 Jul 5;82(13):2403-2416. doi: 10.1158/0008-5472.CAN-21-2352.
Shawn M Davidson 1 2 3,  Daniel R Schmidt # 1 3 4,  Julia E Heyman # 1,  James P O'Brien # 1,  Amy C Liu # 1,  William J Israelsen 1 2,  Talya L Dayton 1 2,  Raghav Sehgal 5,  Roderick T Bronson 1,  Elizaveta Freinkman 6,  Howard H Mak 1,  Giuseppe Nicolò Fanelli 7 8,  Scott Malstrom 1,  Gary Bellinger 1 4,  Arkaitz Carracedo 4,  Pier Paolo Pandolfi 4,  Kevin D Courtney 9,  Abhishek Jha 5,  Ronald A DePinho 9,  James W Horner 9,  Craig J Thomas 10,  Lewis C Cantley 4 7,  Massimo Loda 7 9,  Matthew G Vander Heiden 1 2 3 9
Affiliations

Affiliations

  • 1 Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • 2 Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • 3 Broad Institute of MIT and Harvard University, Cambridge, Massachusetts.
  • 4 Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • 5 Elucidata, Cambridge, Massachusetts.
  • 6 Whitehead Institute, Cambridge, Massachusetts.
  • 7 Weill Cornell Medical College, New York, New York.
  • 8 Division of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • 9 Dana-Farber Cancer Institute, Boston, Massachusetts.
  • 10 National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland.
  • # Contributed equally.
PMID: 35584006 DOI: 10.1158/0008-5472.CAN-21-2352
Abstract

Differential expression of PKM1 and PKM2 impacts prostate tumorigenesis and suggests a potential therapeutic vulnerability in prostate Cancer.

Figures
Products